Compare · CERE vs RPAY
CERE vs RPAY
Side-by-side comparison of Cerevel Therapeutics Holdings Inc. (CERE) and Repay Holdings Corporation (RPAY): market cap, price performance, sector, and recent activity on the wire.
Summary
- CERE operates in Health Care, while RPAY operates in Consumer Discretionary - the two are in different parts of the market.
- RPAY carries a market cap of $363.4M.
- RPAY has hit the wire 7 times in the past 4 weeks while CERE has been quiet.
- CERE has more recent analyst coverage (19 ratings vs 15 for RPAY).
- Company
- Cerevel Therapeutics Holdings Inc.
- Repay Holdings Corporation
- Price
- -
- -
- Market cap
- -
- $363.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Business Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2018
- News (4w)
- 0
- 7
- Recent ratings
- 19
- 15
Cerevel Therapeutics Holdings Inc.
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in Phase Ib clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III clinical trials for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder. It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Repay Holdings Corporation
Repay Holdings Corporation provides integrated payment processing solutions to industry-oriented markets. Its payment processing solutions enable consumers and businesses to make payments using electronic payment methods. The company offers a range of solutions relating to electronic payment methods, including credit and debit processing, virtual credit card processing, automated clearing house (ACH) processing, enhanced ACH processing, and instant funding. It provides payment processing solutions to customers primarily operating in the personal loans, automotive loans, receivables management, and business-to-business verticals. The company sells its products through direct sales representatives and software integration partners. Repay Holdings Corporation was founded in 2006 and is headquartered in Atlanta, Georgia.
Latest CERE
- Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors
- SEC Form 15-12G filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- Former 10% Owner Pfizer Inc closing all direct ownership in the company (SEC Form 4)
- Amendment: SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc.
- Director Bain Capital Investors Llc returned 65,679,781 shares to the company (SEC Form 4)
- Director Gordon Christopher R returned 65,693,524 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest RPAY
- Amendment: SEC Form SCHEDULE 13G/A filed by Repay Holdings Corporation
- Stephens resumed coverage on Repay Holdings with a new price target
- SEC Form 10-Q filed by Repay Holdings Corporation
- Repay Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- REPAY Reports Third Quarter 2026 Financial Results
- General Counsel Dempsey Tyler B sold $118,750 worth of shares (25,000 units at $4.75) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 416,251 units (SEC Form 4)
- REPAY to Announce Third Quarter 2026 Results on November 9, 2026
- General Counsel Dempsey Tyler B sold $55,583 worth of shares (13,888 units at $4.00) as part of a pre-agreed trading plan (SEC Form 4)
- REPAY Enables Embedded Payments for Emburse, Bringing Automation and Control to Spend
- REPAY to Host Investor Day on December 7, 2026